Siponimod (Novartis) Drug Analysis 2018: A Sphingosine-1-phosphate (S1P) Agonist with Selectivity for the S1P1 and S1P5 Receptor Subtypes - ResearchAndMarkets.com

The "Drug Analysis: Siponimod" drug pipelines has been added to ResearchAndMarkets.com's offering.

Siponimod (Novartis) is a sphingosine-1-phosphate (S1P) agonist with selectivity for the S1P1 and S1P5 receptor subtypes. It is Novartis's follow-on product to Gilenya (fingolimod; Novartis/Mitsubishi Tanabe), although the company is hoping that its binding profile will result in a differentiated clinical profile. It is also unique in that Novartis is developing the drug primarily for secondary progressive multiple sclerosis (SPMS), instead of relapsing-remitting multiple sclerosis (RRMS) where there is a clinical precedent for S1P modulators and a high likelihood of success in clinical development.

Siponimod is currently in Phase III development, with Novartis presenting positive topline results for its 1,530-patient Phase III EXPAND trial in September 2016. Novartis's initial plans were to file siponimod for regulatory approval in 2019. However, it now appears that the company might be considering an earlier regulatory filing in SPMS on the basis of EXPAND's impressive data.

Key Topics Covered:

List of Figures

Figure 1: Siponimod for multiple sclerosis - SWOT analysis

Figure 2: Drug assessment summary of siponimod for multiple sclerosis

Figure 3: Drug assessment summary of siponimod for multiple sclerosis

Figure 4: Siponimod sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25

List of Tables

Table 1: Siponimod drug profile

Table 2: Siponimod Phase III data in multiple sclerosis

Table 3: Siponimod sales for multiple sclerosis across the US, Japan, and five major EU markets, by country M, 2016-25

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/s9vmtt/siponimod?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180219005477/en/